A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of DESF in Pediatric Subjects
← catalyst calendarSponsored by Aquestive Therapeutics (industry) · AQST — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
32actual
Sites
8
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-26 | actual | When the study began enrolling |
| Primary completion | 2025-03-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-21 | actual | The whole study's end, after follow-up |
| First posted | 2026-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Allergic Reaction
Intervention
- Drug: DESF
Primary outcomes
what the primary-completion date above is the date OFCmax
measured 0 to 240 minutes post-dose
AUC0-10
measured 0 to 10 minutes
AUC0-20
measured 0 to 20 minutes
AUC0-30
measured 0 to 30 minutes
AUC0-45
measured 0 to 45 minutes
Permalink · AQST's whole pipeline · Catalyst calendar · Every registered study · What changed